European CHMP recommends approval of tucatinib (Tukysa) for treatment of HER2-positive locally advanced or metastatic breast cancer

Tucatinib is an oral antineoplastic protein kinase inhibitor of HER2 kinase. Its benefits include increased progression free survival and overall survival including in patients with metastases.

European Medicines Agency